Advagene
昱厚生技股份有限公司
Advagene is a Taiwan Emerging Stock Board biotechnology company, as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| AD17002 | — | Phase 1 / Phase 2; completed | COVID-19 | Taiwan | 2023-12-22 | Trial registry |
| AD17002-AI | — | Phase 1 / Phase 2; completed | Allergic Rhinitis | Taiwan | 2025-09-16 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.